Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
- DOI
- 10.1007/s10549-010-0788-0
- Published
- 2010 May
- Container
- Breast cancer research and treatment
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10549-010-0788-0,
title = {Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.},
author = {Barrios CH and Liu MC and Lee SC and Vanlemmens L and Ferrero JM and Tabei T and Pivot X and Iwata H and Aogi K and Lugo-Quintana R and Harbeck N and Brickman MJ and Zhang K and Kern KA and Martin M},
year = {2010},
journal = {Breast cancer research and treatment},
doi = {10.1007/s10549-010-0788-0},
url = {https://doi.org/10.1007/s10549-010-0788-0}
}RIS
TY - JOUR TI - Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. AU - Barrios CH AU - Liu MC AU - Lee SC AU - Vanlemmens L AU - Ferrero JM AU - Tabei T AU - Pivot X AU - Iwata H AU - Aogi K AU - Lugo-Quintana R AU - Harbeck N AU - Brickman MJ AU - Zhang K AU - Kern KA AU - Martin M PY - 2010 JO - Breast cancer research and treatment DO - 10.1007/s10549-010-0788-0 UR - https://doi.org/10.1007/s10549-010-0788-0 ER -
APA
CH, B., MC, L., SC, L., L, V., JM, F., T, T., X, P., H, I., K, A., R, L., N, H., MJ, B., K, Z., KA, K., & M, M. (2010). Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-010-0788-0
Source records
- pubmed · retrieved 2026-09-25T06:11:35.753Z